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INTRODUCTION 
Fungal infections are increasingly recognized as a major global health 
problem. There are more than 300 million people afflicted by a serious 
fungal infection resulting in nearly 1.4 million deaths annually. The 
majority of these infections caused by Candida, Aspergillus and 
Cryptococcus species. 
Several risk factor contribute to invasive candidiasis, such as use of broad-
spectrum antibiotics and chemotherapy-induced neutropenia (>500 
neutrophil granulocyte/μl). According to a study which include many 
countries the mortality rate due to candidaemia in all hospital ward was 
29%, however in the intensive care units 60-70% mortality rates have been 
reported. 
Although the prevalence of different Candida species have changed over 
the last decades, 90% of invasive infections are attributed to five species: C. 
albicans, C. glabrata, C. parapsilosis, C. tropicalis and C. krusei. The most 
frequently isolated species is still C. albicans. However the therapeutic and 
prophlytactic FLU administration resulted an epidemiological shift towards 
non-albicans species with primer fluconazole (FLU) resistance (C. krusei) 
or reduced FLU susceptibility (C. glabrata). 
Due to the problems with earlier antifungal agents (toxicity and resistance) 
the milestone of the antifungal chemotherapy was the introduction of 
echinocandins which inhibit glucan synthase responsible for fungal cell wall 
biosynthesis. Caspofungin (CAS) was the first echinocandin approved for 
the treatment of invasive candidiasis and invasive aspergillosis. CAS shows 
fungicide in vitro activity against Candida spp., have favourable 
pharmacokinetics and pharmacodynamics. Therefore CAS is recommended 
as first-line agent for empirical treatment of invasive candidiasis. 
The echinocandins show concentration-dependent killing. Their efficacy 
best correlate with Cmax/MIC (peak concentration in serum/minimal 
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inhibitory concentration) and AUC/MIC (area under plasma the 
concentration-time curve) pharmacodynamics parameters. The approved 
dosing strategy of CAS is 70 mg loading dose than 50 mg daily dose. 
Because of concentration-dependent activity the higher echinocandin doses 
may hypothetically produce better clinical outcomes. The daily 150 mg 
CAS dose can be used for the treatment of invasive candidiasis without 
causing any severe side effects. Nevertheless clinical studies have not 
already confirm that the increased doses may lead to better outcome 
compared to the standard daily doses. 
Echinocandins at drug concentration above the MIC show fungistatic effect 
in spite of the fact that these agents at low concentrations exert fungicide 
activity against certain Candida species (C. albicans, C. tropicalis, C. 
parapsilosis, C. krusei, C. dubliniensis). This paradoxical growth could 
appear at concentrations achievable in human serum, but the clinical 
relevance of this phenomenon is questionable. 
We examined the CAS in vitro activity against C. albicans and C. glabrata 
isolates with time-killing methodology. This method provide remarkable 
data concerning the killing activity of antifungal agents as well as their 
pharmacodynamics properties. As echinocandins are highly protein-bound 
antifungals (96.5-99.8%) serum or tissue proteins may alter their activity. 
The aim of our study was to test the in vivo activity of CAS dose escalation 
in a neutropenic murine model against C. albicans and C. glabrata clinical 
isolates. In order to compare in vivo activity to in vitro efficacy, CAS killing 
rate in RPMI-1640 and RPMI-1640 plus 50% serum were determined. 
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AIMS 
We examined the efficacy of dose escalation against the two most 
frequently isolated Candida species in Hungary. 
The aim of our study was: 
 To determine the caspofungin minimal inhibitory concentration 
using standard microdilution against C. albicans and C. glabrata 
isolates and to compare the values to the results of Etest method in 
case of C. albicans isolates. 
 To examine the in vitro efficacy of caspofungin against C. albicans 
and C. glabrata isolates in RPMI-1640 and RPMI-1640+50% 
human serum using time-kill methodology. 
 To determine killing rates exerted by caspofungin against C. 
albicans and C. glabrata isolates. 
 To determine the in vivo efficacy of caspofungin using daily 1, 2, 
3, 5 and 15 mg/kg doses against C. albicans, as well as daily 1, 2, 
3, 5 and 20 mg/kg doses against C. glabrata in neutropenic murine 
model. 
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MATERIALS AND METHODS 
Isolates 
We studied six C. albicans (14171, 18799, 35035, 5265, 10781, 34350), 
four C. glabrata (11900, 9098, 18910, 15242) clinical isolates, four ATCC 
(American Type Culture Collection) reference strains (10231, 90030, 6258, 
22019), and two echinocandin resistant C. albicans (DPL18, DPL20) and C. 
glabrata (DPL27, DPL245) strains. All clinical isolates originated from 
blood samples and were first isolates (isolated prior antifungal 
administration). The C. albicans and C. glabrata isolates were identified by 
API ID32C and Matrix-assisted laser desorption/ionization time of flight in 
the Department of Medical Microbiology, University of Debrecen. The 
echinocandin resistant DPL18 (F641S mutation), DPL20 (F645P mutation), 
DPL27 (S663P mutation) and DPL245 (S629P mutation) isolates were 
originated from David S. Perlin laboratory (Public Health Research 
Institute, New Jersey Medical School-Ruthgers, Newark, New Jersey, 
USA). 
In vitro susceptibility testing 
Two test media were used, RPMI-1640 (referred to as RPMI) as 
recommended by CLSI and RPMI-1640 supplemented with 50% human 
serum from a human male, type AB, Sigma, Budapest, Hungary (referred to 
as 50% serum). CAS MICs in RPMI and in 50% serum were determined 
simultaneously using the standard CLSI broth microdilution method. CAS 
final concentration ranges were 0.015-32 mg/L. ATCC 6258 C. krusei and 
ATCC 22019 C. parapsilosis were used as reference strains. For the fungal 
suspension prepared with 0.5 McFarland density we used 24 h old colonies 
cultured on Sabouraud agar. We used RPMI for the adjustment of starting 
inoculum approximately 103 CFU (Colony Forming Unit)/ml. The 96-well 
ELISA plate also contained yeast control (without antifungal drug) and 
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medium control (without yeast). After 24 h incubation at 35°C MICs were 
determined after 24 h according to the partial inhibition criteria. 
MIC values were also determined using Etest method (AB Biodisk, 
Sweden) for C. albicans isolates. Etest was carried out using freshly 
prepared RPMI agar supplemented with 2% glucose with and without 50% 
human serum. Etest was carried out using 0.5 McFarland density fungal 
suspensions prepared with 24 h old cultures. These suspensions were evenly 
spreaded on the surface of the RPMI agar plates with sterile swabs. After 
the plates were dried we placed the test stripes impregnated with different 
concentrations of CAS onto them. Results were read after 24 hours of 
incubation at 35°C. 
Time-kill studies 
Time-kill studies were performed according to the standardized method of 
Klepser and his colleagues. The in vitro activity of CAS was investigated in 
RPMI-1640 with and without 50% human serum. The examined CAS 
ranges were 0.25-32 mg/L in a final volume of 10 mL. For the echinocandin 
resistant isolates, only the concentrations 8, 16 and 32 mg/L were used. The 
highest CAS concentration was 32 mg/L, because according to clinical data 
the current maximal administrable daily dose (150-200 mg) produce 30.4-
40.6 mg/L geometric peak concentrations in humans. 
We prepared ~105 CFU/mL starting inoculum from each tested isolates 
using densitometer. Aliquots of 100 μL were removed at 0, 4, 8, 12, 24 and 
48 hours from test tubes containing different CAS concentrations, serially 
diluted 10-fold, plated (4x30 μL) onto a single Sabouraud dextrose agar 
plate and incubated at 35°C for 48 hours. We counted the grown colonies 
and determined the CFU according to the degree of dilutions. Time-kill 
curves were prepared using the computer curve-fitting software GraphPad 
Prism 4.03 for Windows. 
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Analysis of in vitro data 
CAS activity was defined as fungicidal when at least 99.9% reduction in 
viable cell count was observed as compared to the starting inocula. Killing 
kinetics at the tested concentrations were analysed in both media. An 
exponential equation was fitted to the mean data at each time point: Nt=N0 × 
e-kt, where Nt is the number of viable yeasts at time t, N0 is the number of 
viable yeasts in the initial inoculum, k is the killing rate, and t is the 
incubation time. Thus killing rate represents the overall killing capability of 
the drug, taking into account of killing at each tested concentrations. 
Negative k values indicate growth and positive k values indicate killing. The 
goodness of fit for each isolate was assessed by the r2 value (r2>±0.8). The 
mean times to achieve the fungicidal endpoint (T99.9=3/k) were calculated 
from the k values for each isolate and concentrations in both media. Killing 
kinetics among isolates was compared using one-way ANOVA with 
Tukey’s post-testing in either RPMI-1640 or 50% serum. The effect of the 
same drug concentration in RPMI-1640 and 50% serum was analysed using 
T test. The result was significant if p<0.05. 
In vivo studies 
Groups of seven to eight female BALB/c mice (20-22 g) were 
immunosuppressed with four doses of cyclophosphamide, i.e. 4 days before 
infection (150 mg/kg), 1 day before infection (100 mg/kg), 2 days 
postinfection (100 mg/kg) and 5 days postinfection (100 mg/kg). The 
Guidelines for the Care and Use of Laboratory Animals was strictly 
followed during maintenance of the animals. Experiments were approved by 
the Animal Care Committee of the University of Debrecen (permission 
number 12/2014). Each group consisted of 7-8 animals. 
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Preparation of the infectious doses 
For the infective doses we plated the isolates onto Sabouraud agar plates on 
two consecutive days and then the renewed strains were plated onto 3-4 
Sabouraud agar plates again. The grown isolates were taken from the 
surface of the agar plates with sterile swab and suspended in sterile saline. 
The suspensions were centrifugated for 4 times per 10 minutes at 3000 g. 
We removed the supernatant from the cells after each centrifugation and 
added 20-25 mL fresh, sterile saline again to them. After the last 
centrifugation we removed the supernatant again and added 8 mL of sterile 
saline to the fungal cells. From this cell suspension we preparated a 10-fold 
dilution in two steps and adjusted the required cell count of the infective 
dose with Burker chamber. The punctuality of the infective dose’s cell 
count was checked by quantitative inoculation. 
Mice were infected with the fungal suspension intravenously (0.2 
mL/mouse) through the lateral tail vein on the fourth day of the 
immunosuppression. The infectious doses of C. albicans and C. glabrata 
was 7.5x104 CFU/mouse and 6.6-8.4x107 CFU/mouse, respectively. For the 
echinocandin-resistant strains, these doses lead to 100% mortality within 
five days, thus the experiments with the resistant strains were repeated with 
a lower inoculum of 2.5x107 CFU/mouse, which did not cause mortality 
during the experiments. 
Antifungal therapy 
Five-day intraperitoneal treatment with daily 1, 2, 3, 5 and 15 mg/kg CAS 
(Cancidas) for C. albicans and daily 1, 2, 3, 5, 20 mg/kg CAS for C. 
glabrata was started after 24 hours. This dosing strategy was based on 
previous pharmacokinetic studies and on previous result of our study group. 
On day six after infection all mice were sacrificed. The kidneys removed 
(both) weighed and homogenized aseptically. Homogenates were diluted 
10 
10-fold, aliquots of 0.1 mL of the undiluted and diluted (1:10) homogenates 
were plated onto Sabouraud agar plates and incubated at 35°C for 48 h. The 
lower limit of detection was 50 CFU/g of tissue. Statistical analysis of the 
kidney burden was performed using the Kruskal-Wallis test with Dunn’s 
post-test for multiple comparisons. The result was significant if p<0.05. 
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RESULTS 
MIC results with standard microdilution and Etest 
Clinical isolates as well as the ATCC type strains were susceptible to CAS 
according to the revised CLSI breakpoints in RPMI. Confirming the result 
from the preliminary experiments, isolates 10781 and 34350 showed PG in 
RPMI. 
Etest MICs were 2-≥8 times higher than MICs observed in the broth 
microdilution. PG was not observed, the inhibition zone was clear for all C. 
albicans clinical isolates. C. albicans and C. parapsilosis ATCC strains 
were susceptible to CAS, while C. krusei ATCC strain was intermediate 
susceptible to CAS. MIC values for the two echinocandin resistant isolates 
were 2 and 32 mg/L. 
MIC values in both methods were 2-16-fold higher in 50% serum when 
compared to the MICs obtained in RPMI without serum for C. albicans. 
Although we used low number of wild-type isolates for MIC testing, it is 
notable that the MIC range was narrower than in RPMI. We also observed 
higher MIC values (4-8-fold) in 50% serum for C. glabrata isolates. PG was 
never observed regardless of the method used. The DPL18, DPL20, DPL27 
and DPL245 isolates were CAS resistant regardless of the medium used. 
Time-kill results in RPMI-1640 and RPMI-1640+50% human serum 
against Candida albicans 
All isolates grew similarly well in both media. The mean time ranges of 
controls to growth 1 log in RPMI and 50% serum were 8.66-9.77 and 8.9-
10.89 hours, respectively. In RPMI CAS against 14171 and 35035 isolates 
produced fungistatic effects, however, at lower (0.25 and 1 mg/L) 
concentration CFU decreased were higher than at 16 and 32 mg/L 
concentrations. Against isolate 18799, CAS was fungicidal at ≥4 mg/L. In 
cases of 5265, 10781 and 34350 isolates typical PG was observed, 
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fungicidal activity of CAS at lower concentrations and fungistatic effects at 
16 and 32 mg/L. The T99.9 values for these three isolates at 1-8 mg/L were 
short (<12 hours). CAS in 50% serum produced fungistatic effect against 
isolates 14171, 18799 and 35035. CAS killing activity in 50% serum was 
increased in case of all three isolates which showed PG in RMPI-1640, all 
of these were killed at 4-32 mg/L within 10 hours. 
Caspofungin killing rates against Candida albicans isolates 
CAS killing rates (k) were isolate and concentration dependent. There was a 
trend producing higher k values at lower (0.25 or 1 mg/L) concentrations, 
while k values were very low at 32 mg/L. For all isolates k values were 
significantly higher at 1 than at 16 and 32 mg/L (p<0.001). This paradoxical 
effect was the most prominent in cases of 35035 and 5265 isolates where k 
values at 1 and 32 mg/L were 0.314 and 0.295 1/h, and 0.021 and 0.011 1/h, 
respectively. Numerically, the highest k value was observed in case of 
10781 isolate, at 1 mg/L (0.961 1/h). In 50% serum killing rate values at 
0.25 mg/L were negative in cases of isolates 14171, 35035 and 10781, 
indicating that growth occurred. For the remaining three isolates k value 
ranges at 0.25 mg/L were 0.093-0.398 1/h. Killing rates for 18799, 35035, 
5265, 10781 and 34350 isolates were concentration independent at 1-32 
mg/L. The lowest k value range was noticed in cases of isolates 18799 
(0.085-0.109 1/h), while the highest range was found in case of isolate 
10781 (0.882-0.985 1/h). Isolate 14171 behaved differently. Killing rate 
values at 1, 4, 8 and 16 mg/L (k value range was 0.241-0.271 1/h) were 
significantly higher that at 32 mg/L (k value was 0.126 1/h) (p<0.05-0.001). 
Killing rates at 0.25 mg/L were higher in RPMI than in 50% serum for all 
isolates (p<0.05-0.001). In cases of isolates 14171 and 18799 k values were 
significantly higher at all tested concentrations in RPMI than in 50% serum, 
with the exception of 16 mg/L in case of 14171 and 32 mg/L in case of 
18799 isolate (p<0.05-0.001). CAS killing activity at 4-32 mg/L against the 
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remaining isolates increased in 50% serum when compared to RPMI 
(p<0.05-0.001) with the exception of the concentration of 8 mg/L in case of 
5265, and of 4 and 32 mg/L in case of 34350 isolates. 
In vivo efficacy of caspofungin against Candida albicans isolates 
All CAS doses decreased the fungal tissue burden for all tested clinical 
isolates. One mg/kg daily CAS did not decreased significantly the fungal 
tissue burden in cases of isolates 18799, 10781 and 34350, moreover 2 
mg/kg also proved to be ineffective in case of isolates 10781. However, 
CAS doses of 3, 5 and 15 mg/kg proved to be effective for all isolates 
(p<0.05-0.001). The largest CAS dose produced the highest mean fungal 
tissue burden decreases in cases of isolates 18799, 5265 and 10781. 
Numerically, CAS doses of 2, 3 and 2 mg/kg produced the lowest mean 
fungal tissue burden in cases of isolates 14171, 35035 and 34350, 
respectively. However statistically significant differences between the 
effective doses were never observed. 
Time-kill results in RPMI-1640 and RPMI-1640+50% human serum 
against Candida glabrata 
All isolates grew significantly better in RPMI-1640 than in 50% serum. 
Without drug, the mean time to achieve 1 log increase in CFU in RPMI-
1640 and 50% serum was 8.14 and 11.17 hours, respectively, for the clinical 
isolates and 8.57-8.95 and 14.76-14.86 hours, respectively, for the resistant 
isolates. In RPMI-1640, CAS killing activity was better at 1 and 4 mg/L 
than at 16 and 32 mg/L against all clinical isolates. The mean times to 
achieve 99.9% growth reduction from the starting inoculum were shorter 
than 7 hours for isolates 9098, 18910 and 15242 and for the ATCC type 
strain. CAS at 16 and 32 mg/L was fungistatic against strain DPL27, but for 
strain DPL245, a weak and transient fungistatic effect was observed at 32 
mg/L during the first 8 hours in the killing study. In 50% serum the time to 
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reach the fungicidal effect was significantly shorter (≤3.32 hours) than in 
RPMI-1640. The killing activity of CAS in 50% serum was better at 32 
mg/L than in RPMI-1640, even against the resistant strain DPL27. 
Caspofungin killing rates against Candida glabrata isolates 
The CAS killing rates for clinical isolates 11900, 18910, 9098 and the 
ATCC strain were paradoxically higher at 0.25 and 1 mg/L than 16 and 32 
mg/L (p<0.05-0.001). In case of isolate 15242, the k values were 
significantly higher at 0.25, 1 and 32 mg/L than 4, 8 and 16 mg/L, but did 
not differ significantly from each other. Numerically, the highest k values 
were observed with isolate 9098 at 1 and 4 mg/L (1.058 1/h). The lowest k 
value was noted with isolate 11900 at 32 mg/L (0.177 1/h). For the two 
echinocandin resistant strains, the k values were always negative (indicating 
growth) with the exception of the DPL27 isolate at 32 mg/L. 
In 50% serum the killing rate values at 0.25 mg/L showed a wide range, the 
k value was negative (indicating growth) for isolate 11900 (-0.059 1/h), but 
positive (indicating killing) for isolates 9098 (0.916 1/h), 18910 (0.006 1/h) 
and 15242 (0.265 1/h) and for the ATCC strain (0.031 1/h). The killing rates 
at 4-32 mg/L for isolates 11900, 18910, 9098 and 15242 were concentration 
independent (p>0.05 for all comparisons). For the ATCC strain, the highest 
k value was detected at 16 mg/L (1.426 1/h), the k values at 1, 4, 8 and 32 
mg/L (range 1.022-1.085 1/h) did not differ significantly. The k values for 
the DPL245 strain were uniformly negative at 8-32 mg/L, but for the 
DPL27 isolate, the k values at 16 and 32 mg/L were 0.065 and 0.354 1/h, 
respectively. 
The k values at 0.25 mg/L with the exception of isolate 9098 were higher in 
RPMI-1640 than in 50% serum for all isolates (p<0.05-0.001). The killing 
activity of CAS in 50% serum was significantly higher at 4-32 mg/L than in 
RPMI-1640 for isolates 9098, 18910 and 11900 and for the ATCC strain 
(p<0.05-0.001). For isolate 15242 at 4, 8 and 16 mg/L the k values were 
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higher in 50% serum than in RPMI-1640 (p<0.05-0.001), but at 32 mg/L, a 
significant difference was not observed. For DPL27, the killing rates at 16 
and 32 mg/L (0.07 and 0.36 1/h, respectively) were significantly higher in 
50% serum than in RPMI-1640. 
In vivo efficacy of caspofungin against Candida glabrata isolates 
The initial inoculum used (7x107 cell/mL) killed all mice before the pre-
determined endpoint, dead animals showed consistent increase in fungal 
burden over time [6.8x107 and 7.2x106 cells/ kidney tissue (g) at day 2 p.i. 
to 4.3x108 and 6.8x107 cells/ kidney tissue (g) at day 5 p.i. for DPL27 and 
DPL245, respectively]. In contrast, all mice infected with susceptible 
isolates survived, with a mean fungal burden of between 107 and 108 cells/ 
kidney tissue (g) at day 6 p.i. in untreated controls. For this reason resistant 
isolates were tested at a lower infectious dose to harmonize the endpoint for 
all tested isolates. 
At the beginning of therapy (day 1), the mean fungal tissue burden ranges 
for clinical isolates and resistance strains (DPL27 and DPL245) in untreated 
control mice were 4.4x106–6.7x106 and 9.7x106–1.4x107 cells/ kidney tissue 
(g) per mouse, respectively. All mice in all groups survived. All tested 
isolates, except isolate 11900, grew <1 mean log unit in untreated control 
mice as determined at day 6. All caspofungin doses decreased the fungal 
tissue burden signiﬁcantly for all tested clinical isolates compared with the 
controls. However, the mean fungal tissue burdens never fell below 105 
cells/g, and statistically signiﬁcant differences between the ﬁve treatment 
regimens were not observed. Paradoxically decreased activity of 
caspofungin by 20 mg/kg was also not observed. Against the echinocandin-
resistant strains, caspofungin was ineffective regardless of the elevated 
doses. However, for isolate DPL27 but not for DPL245, growth inhibition 
was observed compared with the control at day 1 with all three treatment 
regimens. 
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DISCUSSION 
Mean mortality rate is species dependent, the highest for C. krusei and C. 
glabrata (50-70%) and the lowest in case of C. parapsilosis (20-30%). The 
trend in the mortality did not change radically in the last decade, despite 
echinocandins were introduced into the antifungal armamentarium. 
In our study we used two types of serum-based susceptibility methods 
(broth microdilution and Etest) to determine the MIC values for wild-type 
and echinocandin resistant strains. In order to detect PG by Etest, we used 
RPMI with and without 50% serum. The serum-based Etest showed good 
correlation with serum-based broth microdilution, hence, it may be 
applicable to determine caspofungin MICs both in case of susceptible and 
resistant isolates of C. albicans. As serum-based susceptibility methods 
have not yet been standardized, they are not recommended currently for 
routine susceptibility testing of fungi. The issues to be solved in the future 
include the optimal concentration of serum used in the tests, the origin 
(human or animal source), as well as the high cost of serum. However, 
serum from animals (i.e. bovine serum) may replace human serum in the 
laboratories, decreasing the cost of serum-based MIC determinations. 
Testing higher number of clinical Candida isolates with serum may provide 
a sufficient database to determine new epidemiological cutoff values and 
possible new clinical breakpoints for caspofungin against Candida species. 
In our study we used six clinical isolates which showed diverse behavior in 
killing studies using RPMI as test medium; caspofungin was fungicidal 
against one isolate, was fungistatic against two isolates and three isolates 
showed PG. Decreased activity of caspofungin at higher (16-32 mg/L) 
concentrations was confirmed by the lower k values for all isolates in 
RPMI. In agreement with other studies CAS showed excellent in vitro 
activity against WT clinical isolates as well as against the ATCC 90030 
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type strain. However, in RPMI-1640, caspofungin killing activity decreased 
at 16–32 mg/L when compared with the killing at 0.25–1 mg/L. 
In 50% serum we observed 2-16-fold higher MIC values for C. albicans 
isolates and 4-8-fold higher MICs for C. glabrata isolates than in RPMI-
1640. Paradoxically decreased activity of higher concentration of CAS was 
eliminated by 50% serum both in MIC and in time-kill tests. Fifty percent 
serum restored the killing activity of CAS at higher concentrations as 
revealed by k values. On the contrary, in case of isolate 14171 the killing 
rate was higher at 32 mg/L in RPMI than in 50% serum. 
In 50% serum the killing rate exerted by CAS showed concentration 
independent activity at the effective concentrations (where CFU decreases 
were observed) so after we achieved the first effective concentration, 
concentration enhancement did not produce significant changes in the 
killing activity of CAS. This can be associated with the protein-binding 
characteristic of echinocandins, therefore the pharmacological active drug 
concentration did not increase such extent that it would enhance the killing 
activity. CAS activity was concentration independent at 1-32 mg/L (except 
14171) for C. albicans and at 4-32 mg/L for C. glabrata. Nevertheless k 
values showed a great variability among isolates (0,085-0,985 1/h; and 
0,480-1,536 1/h). 
We expected that isolates showing higher k values of caspofungin either in 
RPMI or in 50% serum will produce better efficacy in a severely 
neutropenic murine model, especially at the largest dose. The utilized doses 
namely 1 mg/kg/day is equivalent with 35 mg/day for humans, 2 mg/kg/day 
is equivalent with 50 mg/day for humans. Based on AUC values 3 and 5 
mg/kg/day are equivalent with 70 mg once and 50 mg/day as well as 70 
mg/day for humans. 
Caspofungin produced concentration-dependent in vivo efficacy against the 
clinical isolates and the ATCC type strain, i.e. concentrations 3, 5 and 15 
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mg/kg, but not 1 and 2 mg/kg were uniformly effective against all tested 
strains. Statistically significant differences between the effective doses was 
not observed, thus dose escalation did not produce better clinical outcomes. 
Moreover, the largest (15 mg/kg) caspofungin dose not only did not produce 
significantly better fungal tissue burden decrease than the lower effective 
doses 3 and 5 mg/kg, but sometimes the highest numerical decrease was 
found in case of lower doses. These in vivo results also confirm that PG has 
no effect on the in vivo efficacy of caspofungin against C. albicans. The 
comparable efficacy of the safely effective doses is in line with the killing 
rate results in 50% serum. 
Contrast with C. albicans, wild-type C. glabrata clinical isolates were 
highly susceptible in vivo to caspofungin even at 1 mg/kg in mice. However 
all treatment arms were unable to reduce the mean fungal burden below 105 
CFU/ g kidney tissue. This suggests that, even at higher doses, only 
suppression of fungal growth can be achieved in severely neutropenic mice 
and thus higher doses do not have a therapeutic beneﬁt compared with 
lower doses. 
Despite the in vitro fungicidal effects, the in vivo activity of caspofungin 
was only fungistatic, in line with previous results. Although immediate or 
early caspofungin treatment may lead to decreased fungal tissue burdens, 
treatment started 24 h after challenge did not. The delay in treatment 
allowed the establishment of high tissue fungal burden in the deeply 
neutropenic host, modelling the most probable clinical situation; in some 
cases, the unfavourable therapeutic response may be the result of delayed 
antifungal treatment. 
Moreover, the randomly selected bloodstream isolates used in the present 
study showed weak replicating ability, as demonstrated both in 50% serum 
and in vivo. The decreased growth of our wild-type C. glabrata isolates in 
50% serum is consistent with a previous report, and the low in vivo growth 
19 
rate suggests a relatively low virulence. Considering this, the extremely 
weak elimination capacity of the treatments was even more notable. A 
potential explanation may lie in the activity of echinocandins; i.e. the slower 
growth in tissues may lead to slower cell wall synthesis, which may, in turn, 
weaken the in vivo killing activity of caspofungin, similarly to what is seen 
with antibacterial agents inhibiting cell wall synthesis. Certainly, other 
factors (e.g. neutropenia, poor drug penetration into the inﬂamed tissues) 
inﬂuence therapeutic outcome. Whether the relatively low in vivo ﬁtness 
found in this study is common among C. glabrata bloodstream isolates, as 
well as its clinical importance, remain to be determined in further studies. 
Although resistance of Candida spp. to echinocandins is low worldwide, 
secondary resistance to caspofungin at some medical centres is more 
substantial. Our preliminary experiments revealed that the virulence of the 
caspofungin-resistant isolates was higher than that of wild-type clinical 
isolates. Moreover, resistant isolates produced slightly higher fungal 
burdens at day 6 p.i. at markedly lower challenge doses. However, the 
susceptible and the resistant isolates were not isogenic. Even higher doses 
were inefﬁcient against isolates with prominent FKS-mediated resistance. 
Our studies conﬁrmed the clinical experience that the efﬁcacy of 
echinocandins is not enhanced by higher CAS doses against echinocandin-
susceptible C. albicans and C. glabrata clinical isolates. The in vitro data 
showed good correlation with the in vivo results. The PG does not influence 
the in vivo activity of CAS. The invasive candidiasis caused by prominent 
FKS mutant strain cannot be treated with high dose CAS in a neutropenic 
host. 
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SUMMARY 
During our investigations killing rate exerted by caspofungin was 
determined in RPMI-1640 with and without 50% human serum against C. 
albicans and C. glabrata clinical and echinocandin resistant isolates. 
Moreover the activity of different daily caspofungin doses were investigated 
in neutropenic mouse model in case of the previously mentioned species. 
Caspofungin killing rate (k) in RPMI-1640 at 1 mg/l was higher than at 16 
and 32 mg/L for all C. albicans isolates. In the same medium caspofungin at 
1 and 4 mg/L showed fungicidal effect within 7 hours against three C. 
glabrata isolates but was only fungistatic at higher concentrations (16 and 
32 mg/L) (paradoxically decreased killing activity). Caspofungin is highly 
protein-bound antifungal agent (96.5%), therefore it possess reduced 
activity in medium supplemented with serum. However adding 50% serum 
eliminated paradoxical growth. In the presence of 50% serum killing rates 
for C. albicans isolates were concentration independent between 1-32 mg/L 
(except one isolate). Similarly concentration independent killing was 
observed at 4-32 mg/L against C. glabrata isolates. Nevertheless k values 
showed a great variability among isolates (0,085-0,985 1/h; and 0,480-1,536 
1/h). Daily 3, 5 and 15 mg/kg caspofungin was effective in a neutropenic 
murine model against all C. albicans isolates, without significant 
differences between the effective doses. All caspofungin doses (1, 2, 3, 5 
and 20 mg/kg/day) decreased the fungal tissue burdens significantly in the 
case of C. glabrata isolates without statistical differences between doses, 
but the mean fungal tissue burdens never fell below 105 cells/g tissue. The 
echinocandin-resistant C. glabrata strains were highly virulent and all doses 
were ineffective. According to our in vitro and in vivo results caspofungin 
dose escalation does not improve efficacy against C. albicans and C. 
glabrata isolates. In addition paradoxical growth does not affect the in vivo 
efficacy of caspofungin. 
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